| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.24▲ | 4.25▼ | 4.27▼ | 4.21▲ | 4.22▲ |
| MA10 | 4.24▲ | 4.27▼ | 4.27▼ | 4.25▼ | 4.01▲ |
| MA20 | 4.24▲ | 4.26▼ | 4.26▼ | 4.20▲ | 4.13▲ |
| MA50 | 4.26▼ | 4.23▲ | 4.31▼ | 3.95▲ | 3.59▲ |
| MA100 | 4.26▼ | 4.30▼ | 4.26▼ | 4.12▲ | 2.43▲ |
| MA200 | 4.25▼ | 4.25▼ | 4.14▲ | 3.93▲ | 1.96▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | -0.005▼ | 0.001▲ | -0.011▼ | -0.003▼ |
| RSI | 48.304▼ | 48.613▼ | 48.853▼ | 52.675▲ | 54.194▲ |
| STOCH | 28.889 | 32.487 | 46.964 | 30.941 | 70.538 |
| WILL %R | -50.000 | -76.667▼ | -47.917 | -67.935 | -50.309 |
| CCI | 30.739 | -84.015 | -16.458 | 4.722 | 53.184 |
|
Saturday, May 16, 2026 06:33 AM
Precigen, Inc. ( NASDAQ:PGEN ) investors will be delighted, with the company turning in some strong numbers with ...
|
|
Wednesday, May 13, 2026 11:20 PM
Precigen Inc (PGEN) reports significant revenue increase driven by Papcimius uptake, despite facing operational losses and rising expenses.
|
|
Wednesday, May 13, 2026 09:12 PM
Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company's first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025. On ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/05/26 | 4.255 | 4.36 | 4.195 | 4.245 | 1,464,738 |
| 21/05/26 | 4.18 | 4.305 | 4.12 | 4.28 | 2,155,050 |
| 20/05/26 | 4.22 | 4.365 | 4.19 | 4.27 | 3,079,510 |
| 19/05/26 | 4.05 | 4.255 | 3.98 | 4.16 | 2,948,701 |
| 18/05/26 | 4.42 | 4.455 | 3.95 | 4.07 | 5,169,641 |
| 15/05/26 | 4.54 | 4.63 | 4.36 | 4.42 | 3,611,976 |
| 14/05/26 | 4.58 | 4.87 | 4.32 | 4.60 | 9,709,929 |
| 13/05/26 | 4.07 | 4.225 | 4.0355 | 4.15 | 2,431,825 |
| 12/05/26 | 4.16 | 4.18 | 4.02 | 4.08 | 2,299,087 |
| 11/05/26 | 4.25 | 4.34 | 4.19 | 4.20 | 1,920,201 |
|
|
||||
|
|
||||
|
|